The FDA has approved five medicines that target BCMA for myeloma as of January 2024. An antibody-drug conjugate (ADC) targeting CD30, Brentuximab vedotin, has also been approved by the FDA to ...

Advances in protein structure prediction tools, such as AlphaFold and ColabFold, have enabled the modeling of complex ...

Preassociation may also be critical for rapid transmembrane signaling, even with low receptor expression, and allow specific transmembrane signals to be generated by TNFR family members that share ...